Working… Menu
Trial record 43 of 419 for:    TRANEXAMIC ACID

Tranexamic Acid in Adherent Placenta (TAP)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02329756
Recruitment Status : Withdrawn (More preparation needed prior to collecting data.)
First Posted : January 1, 2015
Last Update Posted : August 23, 2018
Information provided by (Responsible Party):
Karin Anneliese Fox M.D., M.Ed., Baylor College of Medicine

Brief Summary:
The objective of this study is to investigate the effect of tranexamic acid (TXA) administration on the outcome of cesarean-hysterectomy in women with suspected Morbidly Adherent Placenta (MAP; placenta accreta, increta, percreta).

Condition or disease Intervention/treatment Phase
Placenta Accreta Drug: Tranexamic Acid (TXA) Drug: Sodium Chloride 0.9% Phase 3

Detailed Description:

This trial is a randomized, double blind, placebo controlled trial to quantify the effects of the preoperative administration of tranexamic acid on estimated blood loss and blood product utilization in women undergoing cesarean-hysterectomy for suspected MAP. Subgroup analyses will be performed for laboratory results (coagulation studies, electrolytes, complete blood count), urine output, hemodynamic parameters, return to OR for continued bleeding, post-operative complications (thromboembolism, wound separation, infection, fever), and length of hospital stay. Eligible patients will be randomized to receive either TXA or placebo.

Women eligible for inclusion will be identified during their prenatal course or on admission to the hospital prior to surgery. They will be offered participation in the study after appropriate counseling regarding the equipoise regarding TXA and its use in pregnancy, and following a question and answer period they will be consented, and assigned a study number.

A randomization table will be generated by the Texas Children's Hospital Investigational Pharmacy, using balanced blocks of 8, and will maintain control of the randomization to ensure blinding of participants and the clinical investigators. Randomization will occur when an order for study medication will be sent on a paper requisition to the Texas Children's Hospital Investigational Pharmacy, and a randomization number will be assigned to correspond to the study number. Ideally, this order will be sumbitted 24h prior to scheduled surgery, but may be submitted for urgent cases by calling the Texas Children's Clinical Pharmacy, and delivering the paper requisition to the 7th Floor Main Pharmacy.

The Investigational Pharmacy will prepare study medication (Tranexamic acid I.V. or Normal saline as placebo) as determined by the randomization. The medication (whether study medication or placebo) will be packaged in identical syringes. Sealed, opaque envelopes will be available to the PI or an assigned designee to permit unblinding (linking randomization number and study number) only in the event of a clinical emergency involving a study partipant during times at which the Investigational Pharmacy is closed (nights, weekends, holidays).

Once a patient has been randomized, the outcome in hospital will be collected even if the study medication is interrupted or not actually given.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description: Study drug and placebo will be prepared by Investigational Pharmacy, and with similar appearing packaging and syringes. The Investigational Pharmacy will maintain the randomization table and allocation list. Participants, care providers, investigators and outcomes assessors will remain blinded until after data analysis completed, unless unblinding required in case of clinical emergency, per the unblinding procedures within the protocol.
Primary Purpose: Prevention
Official Title: Tranexamic Acid in Adherent Placenta (TAP), a Randomized Clinical Trial
Estimated Study Start Date : December 2018
Estimated Primary Completion Date : December 2020
Estimated Study Completion Date : December 2021

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Active Comparator: Treatment
Tranexamic acid (TXA) will be compared with matching placebo (sodium chloride 0.9%).
Drug: Tranexamic Acid (TXA)
1g Tranexamic Acid (TXA) will be given at the time of delivery. If in 30 minutes, heavy bleeding continues, a 2nd dose will be administered.
Other Name: Cyklokapron

Placebo Comparator: Control
Matching placebo (sodium chloride 0.9%) will be compared with treatment group
Drug: Sodium Chloride 0.9%

Dose 1: 1 gram - to be administered by intravenous injection at an approximate rate of 1 mL/minute to all randomized women approximately 10 minutes prior to induction of anesthesia

Dose 2: 1 gram - If 30 minutes after beginning the cesarean section there is significant bleeding as defined by the need for the transfusion of 4 or more units of blood products, or if there is a rebleed within the 24 hours after the first dose, a second dose may be given. To be administered by intravenous injection at an approximate rate of 1 mL/minute.

The trial treatment injections should not be mixed with blood for transfusion, or infusion solutions containing penicillin or mannitol.

Other Name: NaCl

Primary Outcome Measures :
  1. Estimated blood loss (EBL) [ Time Frame: At patient discharge, upon death or 6 weeks (42 days) after randomization, whichever occurs first ]
    Our data from the past 65 cases of MAPL performed by our team over the past 3 years shows a 2500 +/- 500ml mean blood loss with these surgeries. Using pooled estimates of the reduction in blood loss published in the literature, a 30% reduction is a reasonable expectation.

  2. Blood product requirements [ Time Frame: At patient discharge, upon death or 6 weeks (42 days) after randomization, whichever occurs first ]
    The administration of a fixed dose is more practicable in this study and we have thus selected a fixed dose of 1 gram of TXA 10 minutes prior to induction of anesthesia, followed by a second dose of 1 gram if heavy bleeding is encountered 30 or more minutes after starting the cesarean section which requires the transfusion of 4 or more units of blood products. This is within the dose range which has been shown to inhibit fibrinolysis and provide hemostatic benefit.

  3. Hemoglobin level change post surgery [ Time Frame: At patient discharge, upon death or 6 weeks (42 days) after randomization, whichever occurs first ]
    The level of hemoglobin change will be measured after surgery.

Secondary Outcome Measures :
  1. Thromboembolic events [ Time Frame: From time patient is given treatment up to 12 weeks post-partum. ]
    Data from all thromboembolic events will be documented on CRFs, including but not limited to the amount and severity of events.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 64 Years   (Adult)
Sexes Eligible for Study:   Female
Gender Based Eligibility:   Yes
Gender Eligibility Description:   The inclusion criteria includes pregnant women.
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Ultrasound and/or MRI diagnosed MAPL pregnancy scheduled to have a cesarean hysterectomy
  • The responsible clinician is substantially uncertain as to whether or not to use TXA
  • Consent has been given according to approved procedures

Exclusion Criteria:

  • Women for whom the responsible clinician considers there is a clear indication for TXA should not be randomized
  • Prior known thromboembolic event during pregnancy
  • Known contraindication to TXA (prior adverse reaction)
  • Patient unable to give adequate consent due to emergent cesarean hysterectomy
  • Bleeding prior to incision
  • Prior known thromboembolic event
  • Women with a history of any acute venous or arterial thrombosis including retinal artery/retinal vein occlusion, cerebrovascular accident, myocardial infarction, deep venous thrombosis, pulmonary embolism
  • History of decreased renal function, renal cortical disease, or significant renal tract disease.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02329756

Layout table for location information
United States, Texas
Baylor College of Medicine
Houston, Texas, United States, 77030
Sponsors and Collaborators
Baylor College of Medicine
Layout table for investigator information
Principal Investigator: Michael A Belfort, MD, PhD Baylor College of Medicine
Principal Investigator: Karin A Fox, MD,MEd Baylor College of Medicine

Layout table for additonal information
Responsible Party: Karin Anneliese Fox M.D., M.Ed., Assistant Professor Obstetrics and Gynecology, Baylor College of Medicine Identifier: NCT02329756     History of Changes
Other Study ID Numbers: H-41847
H-41847 ( Other Identifier: Baylor College of Medicine Institutional Review Board )
First Posted: January 1, 2015    Key Record Dates
Last Update Posted: August 23, 2018
Last Verified: August 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes
Keywords provided by Karin Anneliese Fox M.D., M.Ed., Baylor College of Medicine:
Tranexamic Acid
Additional relevant MeSH terms:
Layout table for MeSH terms
Placenta Accreta
Obstetric Labor Complications
Pregnancy Complications
Placenta Diseases
Tranexamic Acid
Antifibrinolytic Agents
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action